{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:42:56Z","timestamp":1777603376266,"version":"3.51.4"},"reference-count":93,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,5,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The introduction of tyrosine kinase inhibitors (TKIs), a treatment of chronic myelogenous leukemia (CML), has largely replaced curative strategies based on allogeneic stem cell transplantation (SCT). Nevertheless, SCT still remains an option for accelerated\/blastic-phase and selected chronic-phase CML. Transplant outcomes can be optimized by peritransplant TKIs, conditioning regimen, BCR-ABL monitoring, and relapse management. Controversies exist in transplant timing, pediatric CML, alternative donors, and economics. SCT continues to serve as a platform of \u201coperational cure\u201d for CML with TKIs and immunotherapies.<\/jats:p>","DOI":"10.1182\/blood-2014-10-567784","type":"journal-article","created":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T00:46:47Z","timestamp":1428454007000},"page":"3230-3235","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century"],"prefix":"10.1182","volume":"125","author":[{"given":"A. John","family":"Barrett","sequence":"first","affiliation":[{"name":"Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sawa","family":"Ito","sequence":"additional","affiliation":[{"name":"Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"3","key":"2019111818304764000_B1","first-page":"138","article-title":"Treatment of blastic transformation of chronic granulocytic leukemia by high dose cyclophosphamide, total body irradiation and infusion of cryopreserved autologous marrow.","volume":"2","author":"Buckner","year":"1974","journal-title":"Exp Hematol"},{"issue":"1","key":"2019111818304764000_B2","first-page":"96","article-title":"Treatment of blastic transformation of chronic granulocytic leukemia by chemotherapy, total body irradiation and infusion of cryopreserved autologous marrow.","volume":"6","author":"Buckner","year":"1978","journal-title":"Exp Hematol"},{"issue":"6174","key":"2019111818304764000_B3","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/bmj.1.6174.1310","article-title":"Cryopreserved peripheral blood cells functioning as autografts in patients with chronic granulocytic leukaemia in transformation.","volume":"1","author":"Goldman","year":"1979","journal-title":"BMJ"},{"issue":"7","key":"2019111818304764000_B4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM197902153000702","article-title":"Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin.","volume":"300","author":"Fefer","year":"1979","journal-title":"N Engl J Med"},{"issue":"8299","key":"2019111818304764000_B5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(82)92735-0","article-title":"Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation.","volume":"320","author":"Clift","year":"1982","journal-title":"Lancet"},{"issue":"8299","key":"2019111818304764000_B6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(82)92736-2","article-title":"Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia.","volume":"320","author":"Goldman","year":"1982","journal-title":"Lancet"},{"issue":"8299","key":"2019111818304764000_B7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0140-6736(82)92737-4","article-title":"Successful allogeneic bone-marrow transplantation for patients in the accelerated phase of chronic granulocytic leukaemia.","volume":"320","author":"McGlave","year":"1982","journal-title":"Lancet"},{"issue":"3","key":"2019111818304764000_B8","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2010-08-301341","article-title":"Three decades of transplantation for chronic myeloid leukemia: what have we learned?","volume":"117","author":"Pavlu","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111818304764000_B9","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation.","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"issue":"12","key":"2019111818304764000_B10","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"issue":"11","key":"2019111818304764000_B11","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood.V83.11.3377.3377","article-title":"Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse.","volume":"83","author":"van Rhee","year":"1994","journal-title":"Blood"},{"issue":"4","key":"2019111818304764000_B12","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1182\/blood.V86.4.1261.bloodjournal8641261","article-title":"Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.","volume":"86","author":"Mackinnon","year":"1995","journal-title":"Blood"},{"issue":"11","key":"2019111818304764000_B13","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/bmt.2014.176","article-title":"An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors.","volume":"49","author":"Adekola","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2019111818304764000_B14","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/bmt.2011.110","article-title":"The EBMT risk score.","volume":"47","author":"Gratwohl","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"2019111818304764000_B15","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111818304764000_B16","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111818304764000_B17","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111818304764000_B18","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ajh.23691","article-title":"Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management.","volume":"89","author":"Jabbour","year":"2014","journal-title":"Am J Hematol"},{"issue":"11","key":"2019111818304764000_B19","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.6004\/jnccn.2013.0157","article-title":"Chronic Myelogenous Leukemia, Version 1.2014.","volume":"11","author":"O\u2019Brien","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"issue":"22","key":"2019111818304764000_B20","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias.","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111818304764000_B21","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111818304764000_B22","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019111818304764000_B23","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2019111818304764000_B24","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111818304764000_B25","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2010-09-308510","article-title":"Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase.","volume":"117","author":"Jiang","year":"2011","journal-title":"Blood"},{"issue":"13","key":"2019111818304764000_B26","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1182\/blood-2010-08-302679","article-title":"Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.","volume":"117","author":"Jabbour","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111818304764000_B27","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/bmt.2011.194","article-title":"Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.","volume":"47","author":"Khoury","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2019111818304764000_B28","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111818304764000_B29","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1182\/blood-2006-06-031682","article-title":"The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.","volume":"109","author":"Oehler","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111818304764000_B30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.22778","article-title":"Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"issue":"9","key":"2019111818304764000_B31","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/sj.bmt.1704231","article-title":"The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.","volume":"32","author":"Sloand","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2019111818304764000_B32","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2002-02-0535","article-title":"Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase.","volume":"101","author":"Or","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2019111818304764000_B33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/sj.bmt.1704107","article-title":"Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia.","volume":"32","author":"Das","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2019111818304764000_B34","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2007-04-085969","article-title":"Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.","volume":"110","author":"Kebriaei","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2019111818304764000_B35","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00277-011-1349-2","article-title":"Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients.","volume":"91","author":"Topcuoglu","year":"2012","journal-title":"Ann Hematol"},{"issue":"17","key":"2019111818304764000_B36","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1182\/blood-2012-02-409763","article-title":"Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.","volume":"119","author":"Warlick","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019111818304764000_B37","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/leu.2014.145","article-title":"Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis.","volume":"28","author":"Stern","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"2019111818304764000_B38","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/ajh.23263","article-title":"Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: risk stratified approach with a long-term follow-up.","volume":"87","author":"Zuckerman","year":"2012","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111818304764000_B39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/10428190802626624","article-title":"Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.","volume":"50","author":"Poir\u00e9","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019111818304764000_B40","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.bbmt.2013.01.007","article-title":"Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia.","volume":"19","author":"Arpinati","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2019111818304764000_B41","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2005-08-3320","article-title":"Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.","volume":"107","author":"Kaeda","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2019111818304764000_B42","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1182\/blood-2007-10-118141","article-title":"Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia.","volume":"111","author":"Heaney","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2019111818304764000_B43","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","article-title":"Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.","volume":"109","author":"Carpenter","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2019111818304764000_B44","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/leu.2010.83","article-title":"Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia.","volume":"24","author":"Nakasone","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"2019111818304764000_B45","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/leu.2008.401","article-title":"Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase.","volume":"23","author":"Luo","year":"2009","journal-title":"Leukemia"},{"issue":"11","key":"2019111818304764000_B46","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.2009.26.7757","article-title":"Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.","volume":"28","author":"Goldman","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111818304764000_B47","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment.","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111818304764000_B48","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2302\/kjm.52.182","article-title":"Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation.","volume":"52","author":"Ullmann","year":"2003","journal-title":"Keio J Med"},{"issue":"9","key":"2019111818304764000_B49","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.leu.2403068","article-title":"Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.","volume":"17","author":"Olavarria","year":"2003","journal-title":"Leukemia"},{"issue":"2","key":"2019111818304764000_B50","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/sj.bmt.1704332","article-title":"Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment.","volume":"33","author":"Kim","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"2019111818304764000_B51","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1158\/1078-0432.CCR-03-0580","article-title":"Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.","volume":"10","author":"DeAngelo","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111818304764000_B52","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood.V100.5.1590.h81702001590_1590_1595","article-title":"Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.","volume":"100","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"issue":"11","key":"2019111818304764000_B53","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.bmt.1705167","article-title":"Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.","volume":"36","author":"Savani","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2019111818304764000_B54","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/pbc.23389","article-title":"Imatinib has adverse effect on growth in children with chronic myeloid leukemia.","volume":"59","author":"Bansal","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2019111818304764000_B55","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3324\/haematol.2012.067447","article-title":"Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.","volume":"98","author":"Giona","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"2019111818304764000_B56","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/pbc.22945","article-title":"Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy.","volume":"56","author":"Hobernicht","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2019111818304764000_B57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bjh.12977","article-title":"Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years.","volume":"167","author":"de la Fuente","year":"2014","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111818304764000_B58","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood-2011-10-380774","article-title":"How I treat childhood CML.","volume":"119","author":"Andolina","year":"2012","journal-title":"Blood"},{"issue":"17","key":"2019111818304764000_B59","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111818304764000_B60","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.bbmt.2013.12.001","article-title":"Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors.","volume":"20","author":"Bevans","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111818304764000_B61","author":"Bevans"},{"issue":"15","key":"2019111818304764000_B62","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1182\/blood-2014-05-578567","article-title":"Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study.","volume":"124","author":"Millot","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019111818304764000_B63","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.6004\/jnccn.2009.0069","article-title":"Issues of imatinib and pregnancy outcome.","volume":"7","author":"Apperley","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"2019111818304764000_B64","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome.","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111818304764000_B65","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2010-04-280206","article-title":"Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response.","volume":"116","author":"Kuwabara","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111818304764000_B66","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/bmt.2011.78","article-title":"Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence.","volume":"47","author":"Borgmann-Staudt","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2019111818304764000_B67","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2010.07.009","article-title":"Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR).","volume":"17","author":"Loren","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2019111818304764000_B68","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1177\/030006051204000640","article-title":"Twin pregnancy and childbirth after reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation combined with imatinib mesylate for chronic myeloid leukaemia: case report and literature review.","volume":"40","author":"Wu","year":"2012","journal-title":"J Int Med Res"},{"issue":"12","key":"2019111818304764000_B69","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s10815-011-9681-y","article-title":"Live birth with vitrified-warmed oocytes of a chronic myeloid leukemia patient nine years after allogenic bone marrow transplantation.","volume":"28","author":"Kim","year":"2011","journal-title":"J Assist Reprod Genet"},{"issue":"8","key":"2019111818304764000_B70","doi-asserted-by":"crossref","first-page":"646","DOI":"10.7326\/0003-4819-120-8-199404150-00004","article-title":"Identical-twin bone marrow transplants for leukemia.","volume":"120","author":"Gale","year":"1994","journal-title":"Ann Intern Med"},{"issue":"11","key":"2019111818304764000_B71","first-page":"3323","article-title":"Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia.","volume":"95","author":"Barrett","year":"2000","journal-title":"Blood"},{"issue":"12","key":"2019111818304764000_B72","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.bbmt.2013.09.008","article-title":"Comparison of unrelated cord blood transplantation and HLA-matched sibling hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in advanced stage.","volume":"19","author":"Zheng","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2019111818304764000_B73","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1016\/j.bbmt.2013.12.358","article-title":"Safety and efficacy of haploidentical stem cell transplantation for advanced chronic myeloid leukemia.","volume":"20","author":"Adekola","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"2019111818304764000_B74","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.","volume":"121","author":"Experts in Chronic Myeloid Leukemia","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2019111818304764000_B75","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/bmt.2008.90","article-title":"Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?","volume":"42","author":"Ruiz-Arg\u00fcelles","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"2019111818304764000_B76","article-title":"Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib [published online ahead of print October 21, 2014].","author":"Ohm","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019111818304764000_B77","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bbmt.2013.02.016","article-title":"The significance of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia.","volume":"19","author":"Goldman","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 3","key":"2019111818304764000_B78","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2012.0184","article-title":"Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure.","volume":"10","author":"Cortes","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"2019111818304764000_B79","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111818304764000_B80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428190500407996","article-title":"Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?","volume":"47","author":"Goldman","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2019111818304764000_B81","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/sj.leu.2404858","article-title":"Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study.","volume":"21","author":"Rojas","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"2019111818304764000_B82","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2007-08-108241","article-title":"Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.","volume":"111","author":"Rezvani","year":"2008","journal-title":"Blood"},{"key":"2019111818304764000_B83","author":"Rezvani"},{"issue":"5","key":"2019111818304764000_B84","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood.V95.5.1781.005k46_1781_1787","article-title":"Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.","volume":"95","author":"Pinilla-Ibarz","year":"2000","journal-title":"Blood"},{"issue":"10","key":"2019111818304764000_B85","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nrclinonc.2010.141","article-title":"Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination.","volume":"7","author":"Bocchia","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"2019111818304764000_B86","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/leu.2013.66","article-title":"Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.","volume":"27","author":"Weber","year":"2013","journal-title":"Leukemia"},{"issue":"26","key":"2019111818304764000_B87","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1182\/blood-2010-09-308569","article-title":"Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia.","volume":"117","author":"Bornh\u00e4user","year":"2011","journal-title":"Blood"},{"issue":"15","key":"2019111818304764000_B88","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111818304764000_B89","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/blood-2008-06-164889","article-title":"Aurora-A kinase: a novel target of cellular immunotherapy for leukemia.","volume":"113","author":"Ochi","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111818304764000_B90","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/leu.2010.325","article-title":"Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein.","volume":"25","author":"Yong","year":"2011","journal-title":"Leukemia"},{"issue":"37","key":"2019111818304764000_B91","doi-asserted-by":"crossref","first-page":"16280","DOI":"10.1073\/pnas.1004408107","article-title":"Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.","volume":"107","author":"J\u00e4r\u00e5s","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"25","key":"2019111818304764000_B92","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood"},{"issue":"22","key":"2019111818304764000_B93","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation.","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/21\/3230\/1386097\/3230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/21\/3230\/1386097\/3230.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T18:32:45Z","timestamp":1574101965000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/125\/21\/3230\/34010\/The-role-of-stem-cell-transplantation-for-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,21]]},"references-count":93,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2015,5,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-10-567784","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,21]]}}}